Gilde Healthcare, a leading specialized healthcare investor, today announced that its portfolio company Noema Pharma, has raised an oversubscribed CHF 103 million ($112 million) Series B financing round from new and existing investors. Noema Pharma is a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders. The financing round was completed by an international syndicate led by new investors Jeito Capital and Forbion and was joined by existing investors Gilde Healthcare, Sofinnova Partners, Polaris Partners and Invus. Also new to the syndicate were UPMC Enterprises and an undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma’s clinical-stage assets including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The Company is also developing gemlapodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
The Series B financing follows a CHF 54M ($60M) Series A financing which concluded in December 2020 in which Gilde Healthcare joined as the largest investor.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over $2B across two fund strategies: venture & growth capital and private equity. The Venture & Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, digital health and medtech. The venture & growth companies are based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.